Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

Based on ODYSSEY Outcomes,which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ulf Landmesser MD, FESC

Ulf Landmesser MD, FESC

Professor of Cardiology
Medical Director, Department of Cardiology
Charite University Hospital
Berlin, Germany